2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159133
    BuChE-IN-13 98%
    BuChE-IN-13 (compound 3) is a BuChE inhibitor and shows anti-Alzheimer activity. BuChE-IN-13 can be used for study of neurodegenerative disease.
    BuChE-IN-13
  • HY-159143
    BChE-IN-33 98%
    BChE-IN-33 (compound 4r), an arylaminonaphthol derivative, is a potent butyrylcholinesterase (BChE) inhibitor with an IC50 of 14.78 µM. BChE-IN-33 also inhibits CYP2C19, CYP2C9, CYP2D6. BChE-IN-33 shows potent antioxidant activity with IC50 values of 150.48 μM, 2.56 μM and 4.61 μM by DPPH, ABTS, Ferric-phenanthroline assay, respectively. BChE-IN-33 has the potential for Alzheimer research.
    BChE-IN-33
  • HY-159146
    PPARα agonist 4 98%
    PPARα agonist 4 (compound BH400) is a PPARα agonist (EC50= 1.2 μM). PPARα agonist 4 also inhibits STING (IC50: 8.1 μM). PPARα agonist 4 reduces the CoCl2-induced production of ROS and LPS-induced secretion of IL-6. The PPARα agonist 4 restores the decreased expression of PCG1α induced by LPS.
    PPARα agonist 4
  • HY-159151
    AChE/Aβ-IN-6 98%
    BACE1-IN-15 (compound 4j) is a potent inhibitor of BACE1 (β-secretase) that can inhibited the copper ion induced Aβ toxicity, with the EC50 of 0.68 μM.
    AChE/Aβ-IN-6
  • HY-159152
    PQM-164 2226535-25-5 98%
    PQM-164 (Compound 3e) has antioxidant activity (IC50: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease.
    PQM-164
  • HY-159171
    sEH/HDAC6-IN-2 3009011-58-6 98%
    sEH/HDAC6-IN-2 is a potent dual soluble epoxide hydrolase (sEH) and HDAC6 inhibitor with IC50s of 0.9 nM, 46.8 nM, and 8 nM for human sEH, mouse sEH, and HDAC6, respectively. sEH/HDAC6-IN-2 can be used for the study of inflammatory pain.
    sEH/HDAC6-IN-2
  • HY-159173
    AChE-IN-71 1708114-58-2 98%
    AChE-IN-71 (compound 12A) is a AChE inhibitor. AChE-IN-71 can be used in the study of Alzheimer’s disease.
    AChE-IN-71
  • HY-159177
    M4 mAChR Modulator-1 98%
    M4 mAChR Modulator-1 (compound 23i) is a M4 mAChR positive allosteric modulator (PAM). M4 mAChR Modulator-1 exhibits significantly greater cooperativity with ACh in β-arrestin recruitment over G protein activation. M4 mAChR Modulator-1 displays weak PAM effect in G protein-mediated responses, but strong PAM effect in β-arrestin recruitment.
    M4 mAChR Modulator-1
  • HY-159482
    SBN-284 98%
    SBN-284 (compound 3x) is a dual inhibitor of blood-brain permeable Cholinesterases and the NLRP3 inflammasome and is effective against EeAChE, hAChE and eqBChE, the IC50 values of are 0.37, 0.31, 0.29 μM respectively, and the EC50 of NLRP3 inflamm is 1 μM. SBN-284 can be used in Alzheimer's disease research.
    SBN-284
  • HY-159492
    5-HT7 receptor ligand 2 98%
    5-HT7 receptor ligand 2 (compound 32) is an arylpiperazinehydrazine ligand for 5-HT7R (Ki=178 nM). 5-HT7 receptor ligand 2 has good membrane permeability, low hepatotoxicity and cardiotoxicity, and high plasma protein binding. 5-HT7 receptor ligand 2 shows neuroprotective effects in SH-SY5Y cells and can be used for the study of central nervous system related diseases.
    5-HT7 receptor ligand 2
  • HY-159567
    Ferroptosis-IN-11 1266755-01-4 98%
    Ferroptosis-IN-11 (compound 43) is a ferroptosis inhibitor. Ferroptosis-IN-11 can inhibit Erastin (HY-15763) induced ferroptosis in HT-1080 human fibroblasts (EC50=36 nM). Ferroptosis-IN-11 can be used in the study of cardiovascular disease and neurodegeneration.
    Ferroptosis-IN-11
  • HY-159584
    LBG20304 98%
    LBG20304 (compound 2s) is a ligand for the homologous GluK5 receptor (IC50: 432 nM), more than 40-fold selective over the homologous GluK1-3 isoforms. Low doses of LBG20304 (<10 μM) have no agonist or antagonist functional response at heterologous GluK2/5 receptors, and at high doses (>10 μM), it exhibits low agonist activity in neuronal slices (rat).
    LBG20304
  • HY-159624
    KK-92A 98%
    KK-92A, a blood-brain barrier penetrated GABAB positive allosteric modulator (PAM), suppresses alcohol self-administration and cue-induced reinstatement of alcohol seeking in rats.
    KK-92A
  • HY-159731
    OX2R agonist 1 2648347-78-6 98%
    OX2R agonist 1 is an OX2R antagonist with an EC50 of less than 100 nM. OX2R agonist 1 can be used in research related to excessive daytime sleepiness or narcolepsy.
    OX2R agonist 1
  • HY-159826
    Brexanolone caprilcerbate 2681264-65-1 98%
    Brexanolone caprilcerbate is a potent GABAA receptor positive allosteric modulator.
    Brexanolone caprilcerbate
  • HY-159829
    Direclidine 1803346-98-6 98%
    Direclidine is a muscarinic M4 receptor positive allosteric modulator.
    Direclidine
  • HY-159832
    Relicpixant 2445366-94-7 98%
    Relicpixant is a potent purinoreceptor (P2X) antagonist.
    Relicpixant
  • HY-159837
    Nispomeben 1443133-41-2 98%
    Nispomeben is a potent non-opioid pain relief drug.
    Nispomeben
  • HY-159880
    AChE/BChE-IN-24 3053509-06-8 98%
    AChE/BChE-IN-24 (compound 5k) is a neuroprotective agent through cholinesterase inhibition. AChE/BChE-IN-24 inhibits AChE and BChE with IC50 values of 16.38 μM and 10.44 μM, respectively.
    AChE/BChE-IN-24
  • HY-159888
    SON38 3034673-37-2 98%
    SON38 is a copper chelator capable of chelating divalent copper. SON38 can inhibit the activity of cholinesterases and has potential applications in Alzheimer's disease research.
    SON38
Cat. No. Product Name / Synonyms Application Reactivity